Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease by E. Nobili et al.
Cysteinyl Leukotriene Signaling Aggravates Myocardial
Hypoxia in Experimental Atherosclerotic Heart Disease
Elena Nobili1,2, M. Dolores Salvado3, Lasse Folkersen5, Laura Castiglioni2, Jens Kastrup4,
Anders Wetterholm3, Elena Tremoli1,2, Go¨ran K. Hansson5, Luigi Sironi1,2, Jesper Z. Haeggstro¨m3*,
Anders Gabrielsen5*
1Monzino Cardiologic Center, IRCCS, Milan, Italy, 2Department of Pharmacology, University of Milan, Milan, Italy, 3Department of Medical Biochemistry (MBB) II,
Karolinska Institutet, Stockholm, Sweden, 4Department of Cardiology B, Cardiac Catheterization Laboratory, Rigshospitalet, Copenhagen, Denmark, 5Department of
Medicine, Exp. Cardiovascular Research, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
Abstract
Background: Cysteinyl-leukotrienes (cys-LT) are powerful spasmogenic and immune modulating lipid mediators involved in
inflammatory diseases, in particular asthma. Here, we investigated whether cys-LT signaling, in the context of
atherosclerotic heart disease, compromises the myocardial microcirculation and its response to hypoxic stress. To this
end, we examined Apoe2/2 mice fed a hypercholesterolemic diet and analysed the expression of key enzymes of the cys-LT
pathway and their receptors (CysLT1/CysLT2) in normal and hypoxic myocardium as well as the potential contribution of
cys-LT signaling to the acute myocardial response to hypoxia.
Methods and principal findings: Myocardial biopsies from Apoe2/2mice demonstrated signs of chronic inflammation with
fibrosis, increased apoptosis and expression of IL-6, as compared to biopsies from C57BL/6J control mice. In addition, we
found increased leukotriene C4 synthase (LTC4S) and CysLT1 expression in the myocardium of Apoe
2/2mice. Acute bouts of
hypoxia further induced LTC4S expression, increased LTC4S enzyme activity and CysLT1 expression, and were associated
with increased extension of hypoxic areas within the myocardium. Inhibition of cys-LT signaling by treatment with
montelukast, a selective CysLT1 receptor antagonist, during acute bouts of hypoxic stress reduced myocardial hypoxic areas
in Apoe2/2 mice to levels equal to those observed under normoxic conditions. In human heart biopsies from 14 patients
with chronic coronary artery disease mRNA expression levels of LTC4S and CysLT1 were increased in chronic ischemic
compared to non-ischemic myocardium, constituting a molecular basis for increased cys-LT signaling.
Conclusion: Our results suggest that CysLT1 antagonists may have protective effects on the hypoxic heart, and improve the
oxygen supply to areas of myocardial ischemia, for instance during episodes of sleep apnea.
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Introduction
Chronic ischemic heart disease is characterized by inadequate
oxygen supply to the myocardium at rest or in response to
increased demand and is usually caused by flow restriction with
normal blood oxygen content. However, under certain circum-
stances reduction in oxygen supply due to decreased blood oxygen
content may be the main eliciting cause of inadequate oxygen
supply to the myocardium, as for example observed during sleep
apnea.
Patients with sleep apnea exhibit a variant number of reductions
and severity of decreased blood oxygen content during sleep.
Notably, systemic leukotrienes are increased in patients with
obstructive sleep apnea and increased LTB4 signaling has been
suggested to contribute to development of atherosclerotic lesions
[1,2,3,4,5]. Furthermore, increased cysteinyl leukotriene (cys-LT)
signaling has been shown to cause vasoconstriction in atheroscle-
rotic coronary vessels [6], suggesting an important role for these
mediators in the cardiovascular response to sleep apnea.
It is therefore possible that during bouts of hypoxia, such as
those seen with sleep apnea disorders, the heart begins to produce
leukotrienes [5,7], pro-inflammatory molecules derived from the
5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism
[8]. Exogenous cys-LTs elicit severe vascular constriction of the
coronaries and cardiac arrhythmias during intracoronary admin-
istration [9] and cys-LT signaling can aggravate myocardial
ischemia-reperfusion injury and infarction, as well as impede
remodeling after myocardial injury in certain experimental models
[10,11]. It is possible that vasoconstrictor and/or pro-inflamma-
tory effects of chronic and acute-in-chronic cys-LT signaling ‘‘per
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se’’ aggravate myocardial hypoxia and inflammation during bouts
of hypoxia and would be particularly detrimental in the setting of
chronic ischemic heart disease.
Such a notion would require that 1) the constitutional
components of the cys-LT pathway are expressed in the
myocardium and 2) that interruption of cys-LT signaling during
bouts of hypoxia is beneficial. Accordingly, we investigated the
gene expression and role of the cys-LT signaling cascade in
a mouse model of atherosclerotic heart disease and compared the
results with gene expression data from specimens of human
myocardium. Specifically, we tested the hypothesis that cys-LT
signaling plays a role in sustaining myocardial ischemia during
bouts of hypoxia in chronic ischemic heart disease.
Results
The Apoe2/2 Mouse as a Model of Chronic Ischemic
Heart Disease
It is well known that Apoe2/2 mice develop hypercholesterol-
emia and atherosclerotic lesions, including the coronaries [12]
whereas wild type control mice (C57BL/6J) do not. Furthermore,
recent reports indicate that Apoe2/2 show cardiac hypertrophy
and interstitial remodeling [13]. When analyzing Apoe2/2 heart
tissue we found similar functional and histopathological changes
(Fig. 1). Thus, heart/body weight ratios were significantly
increased in Apoe2/2 mice compared to C57BL/6J mice
(Fig. 1A). Furthermore, a pronounced increase of interstitial
matrix collagen deposition, detected with sirius red staining, is
present in Apoe2/2 vs. C57BL/6J mice under both normoxic or
hypoxic conditions (Fig. 1B). No evidence of necrotic areas were
observed with hematoxylin/eosin staining and plasma levels of
cardiac troponin I was not changed in C57BL/6J and Apoe2/2
mice after 1 year of a hypercholesterolemic diet under both
normoxic and hypoxic conditions (data not shown). Therefore, no
evidence of myocardial infarction could be demonstrated.
In addition, we analyzed if increased cell apoptosis correlated
with atherosclerotic heart disease, applying a TUNEL staining
procedure. TUNEL positive cells were considerably increased in
Apoe2/2 compared to C57Bl6 mice (Fig. 1C), however, significant
changes in apoptotic cell numbers could not be demonstrated in
response to hypoxia in any of the mice models.
Moreover, we found that the expression of IL-6 was robustly
increased in Apoe2/2mouse hearts as compared to wild type mice
(p,0.05) whereas the expression levels of TNFa, CCL-2, ICAM-
1, and MIB-2 were not significantly altered (Fig. 2). No significant
additional changes in any of these cytokine levels were observed
under hypoxic conditions in the myocardium, making it unlikely
that these mediators were responsible for the effects of hypoxia.
Thus, the fat-fed, aged Apoe2/2 mouse model develops severe
atherosclerosis with myocardial hypertrophy, increased interstitial
collagen deposition, increased apoptosis and a chronic increase in
IL-6 levels without any evidence of myocardial infarction. We
continued to specifically investigate the expression and role of the
cys-LT system.
LTC4S and CysLT1 Gene Expression is Up-regulated in
Cardiac Tissue of Apoe2/2 Mice
We assessed the profile of LT cascade proteins at the mRNA
level. In the Apoe2/2 heart, mRNA levels of LTC4S and CysLT1
were significantly upregulated as compared to control C57BL/6J
mice whereas 5-LO levels remained unaltered (Fig. 3A). Immu-
nohistochemical analyses confirmed the presence of CysLT1
receptor protein expression in mouse heart tissue in Apoe2/2
mice without hypoxia and in Apoe2/2 mice following hypoxic
stress, mostly located in endothelial cells (Fig. 4).
Hypoxic Stress Further Induces Expression of the cys-LT
Pathway
Additional experiments were performed to determine the effects
of acute hypoxic stress on LT pathway gene expression in Apoe2/
2 mice. At 48 h after a bout of hypoxia a further increase in the
expression of LTC4S (p,0.05) and CysLT1 (p,0.05) (Fig. 3B) was
observed. In addition, we found a trend toward a further increase
in the expression of 5-LO, the upstream enzyme in cys-LT
biosynthesis (Fig. 3B).
LTC4S Enzyme Activity is Increased in Cardiac Tissue of
Apoe2/2 Mice
To detect LTC4S enzyme activity, microsomal preparations
were isolated from Apoe2/2 heart tissue and incubated with intact
LTA4, the key unstable intermediate of the LT cascade. Coupled
HPLC/EIA analysis detected significant formation of LTC4,
which increased in heart tissue from Apoe2/2 mice, particularly
following hypoxic stress (Fig. 5).
Blocking cys-LT Signaling Reduces Myocardial Hypoxic
Load
To evaluate the hypoxic load, mouse heart samples were stained
with hypoxyprobe. Hypoxic myocardial load, expressed as %
positive staining area, was significantly enhanced upon acute
hypoxic stress in Apoe2/2 mice. In contrast, no changes were
observed in the hypoxic myocardial area when C57Bl6 mice were
subjected to acute hypoxia. When Apoe2/2 mice were pretreated
with montelukast and subjected to an acute hypoxic stress, the
hypoxic myocardial load decreased to basal normoxic levels (Fig. 6
A and B). It therefore seems likely that cys-LT signaling plays
a more prominent role specifically in diseased tissue and not in
healthy myocardium.
Cys-LT Pathway Gene Expression in the Human Heart
We performed mRNA expression analyses of 5-LO, LTC4S and
the CysLT1 receptor on a unique collection of human heart
biopsies, obtained from chronic ischemic and non-ischemic parts
of the same heart; i.e. each heart biopsy in chronic ischemic area
was compared with a control biopsy from the same patient in
a non-ischemic area. A significant increase in both LTC4S and
CysLT1 mRNA levels was observed in chronic ischemic human
myocardium (compared to non-ischemic myocardium) (Fig. 7), in
agreement with the data obtained with Apoe2/2 mice (Fig. 3A).
Discussion
Leukotrienes are potent pro-inflammatory lipid mediators and
over the past years several studies have implicated LTs, in
particular LTB4, in the inflammatory component underlying
vascular inflammation, atherosclerosis, and atherothrombosis
[8,14,15,16,17,18]. The role of LTs in diseases related to the
myocardium, however, remains unclear. Thus, in previous studies
with preclinical models, hearts of otherwise healthy animals
(rodents and dogs) have been subjected to ischemic damage and
effects of genetic or pharmacological intervention of the leukotri-
ene pathway have been studied with variable effects [19,20]. In
recent elegant studies, the second major receptor for cys-LTs, viz.
CysLT2 has been implicated in vascular responses to cys-LT and
ischemia-reperfusion injury [10,21]. Here, a transgenic model was
employed with artificial overexpression of CysLT2 in endothelial
Leukotriene Signaling in Heart Disease
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Figure 1. Apoe2/2 mouse as a model of atherosclerotic heart disease. Heart weight/animal weight ratios are significantly increased in
Apoe2/2 mice compared to C57BL/6J (**, p,0,01 versus C57BL/6J) (Panel A). Hypercholesterolemic diet led to a strong increase of interstitial matrix
collagen deposition in Apoe2/2 compared to C57BL/6J under both normoxic and hypoxic condition (Panel B left). We analyzed 3 coronal area
sections from each animal and the results are expressed using a semiquantitative score: 1 absent collagen, 2 mild collagen deposition, 3 severe
collagen deposition. Panel B right is a representative image of absent (1), mild (2) and severe (3) collagen deposition. The number of apoptotic cells is
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cells and, as in most previous investigations, the potential impact of
pre-existing vascular disease or atherosclerosis was not addressed.
Furthermore, is important to distinguish between models of
ischemia/reperfusion with infarction and models of hypoxia
without infarction. Accordingly, although studies have addressed
the potential role of LTs in the setting of myocardial infarction and
ischemia-reperfusion injury with influx of inflammatory cells (for
review see [22]) understanding of the coupling between a hypoxic
myocardial environment and induction of LT signaling is lacking.
In particular, it is unclear whether and/or which of the molecular
components of the LT system is expressed in the myocardium and
if production of LTs occur. In addition, it is not known whether
endogenous LT signaling elicits adverse effects in response to bouts
of hypoxia. We therefore constructed an experimental system to
test the hypothesis that cys-LT signaling may compromise the
myocardial oxygen supply in chronic ischemic heart disease during
bouts of hypoxia.
In the present study we chose the Apoe2/2 mouse as a model of
atherosclerotic heart disease and assessed the gene expression
profile of the LT cascade. The Apoe2/2 mouse develops
hypercholesterolemia and extensive atherosclerotic lesions
throughout the arterial tree as well as coronary atherosclerosis
[12]. In addition, this mouse model exhibits cardiac hypertrophy
and interstitial remodeling [13], findings that we were able to
reproduce in this investigation (Fig. 1). We found that in the
Apoe2/2 heart, levels of LTC4S and CysLT1 were specifically and
significantly upregulated as compared to control C57BL/6J mice.
Since LTC4S catalyzes the committed step in cys-LT formation
and the CysLT1 receptor is known to mediate classical pro-
inflammatory actions of cys-LT [23], this expression profile is
consistent with increased cys-LT signaling in the heart in
atherosclerotic disease.
Previous clinical investigations have demonstrated increased
levels of urinary LTE4, a stable and bioactive metabolite of LTC4,
in patients with sleep apnea [4] and acute coronary syndromes [7].
Moreover, treatment with a FLAP inhibitor suppressed bio-
markers of infarction in a clinical trial of patients with a genetic
variant of FLAP that confers increased risk of myocardial
infarction [15]. However, these studies have measured systemic
levels of LTs and none of them have presented direct evidence for
a localized myocardial production of these mediators.
Furthermore, it is not previously known whether an acute
hypoxic stimulus increases the expression of genes involved in LT
production and signaling, which in turn would point to a possible
link between hypoxia and inflammation in the heart. It was
therefore of interest to assess the effects of a bout of hypoxic stress
on LT-pathway gene expression. In our model, there was
a pronounced increase in the expression of LTC4S and CysLT1
in response to hypoxic stress. In addition, we could detect
a tendency towards increased expression of 5-LO, the upstream
enzyme in LT biosynthesis. One could argue that increased
expression of cys-LT system components are due to an increased
influx of inflammatory cells in chronic hypoxic myocardium or
following hypoxic stress. Although a contribution from recruited
leukocytes cannot be entirely excluded it does not appear a likely
explanation to our data, because we had no evidence of
myocardial infarction by histology or troponin measurements
and we counted inflammatory cells and found no differences in
numbers of CD68+ cells.
CysLT1 protein was localized by immunohistochemistry to
vascular (possibly endothelial) cells in heart tissue of Apoe2/2
mice. In the absence of a specific antiserum for LTC4S, we used
a biochemical approach to demonstrate the presence of active
enzyme in the mouse myocardium. Thus, incubation of heart
significantly increased in Apoe2/2 compared to C57BL/6J only under normoxic condition. We performed TUNEL staining on 3 coronal area sections
from each animal and results are expressed as mean of number of apoptotic cells (*, p,0.05 versus C57BL/6J normoxia) (Panel C left). Panel C right is
a representative image of positive TUNEL staining (1, arrow) and overlap with propidium iodide as a nuclei marker (2, arrow). Results presented are
mean6SD of C57BL/6J normoxia n = 4; C57BL/6J hypoxia n = 5; Apoe2/2 normoxia n = 6; Apoe2/2 hypoxia n = 7.
doi:10.1371/journal.pone.0041786.g001
Figure 2. IL-6 expression is upregulated in cardiac tissue of Apoe2/2 mice. In the Apoe2/2 mouse model, baseline heart levels of IL-6 are
increased as compared to control C57BL/6J mice whereas levels of TNF-a, Ccl2, ICAM-1, MIB-2 are unaltered. Each experiment was run in duplicate
and changes in mRNA levels were expressed as DDCt values and presented as relative to the mean of C57BL/6J mice. Values are mean6SD of C57BL/
6J n = 4; Apoe2/2 n= 6. *, p,0.05.
doi:10.1371/journal.pone.0041786.g002
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membrane preparations with intact LTA4, followed by analysis
with HPLC coupled to EIA, revealed significant formation of
LTC4, which increased in heart tissue from Apoe
2/2 mice,
particularly following hypoxic stress. Because there is only one
membrane enzyme with significant ability to conjugate LTA4 with
GSH to form LTC4, i.e., LTC4S, we conclude that this enzyme is
up-regulated in hypoxic heart tissue from Apoe2/2 mice.
To test whether pharmacological interruption of the cys-LT
signaling pathway could have an impact on the hypoxic load of the
myocardium, Apoe2/2 mice were subjected to hypoxia in the
presence or absence of montelukast, a selective antagonist of
Figure 3. LTC4S and CysLT1 are upregulated in cardiac tissue of Apoe
2/2 mice. In the Apoe2/2 heart, levels of LTC4S and CysLT1 are
significantly upregulated as compared to control C57BL/6J mice (Panel A). Acute hypoxic stress in Apoe2/2 mice increases the cardiac expression of
LTC4S (p,0.05) and CysLT1 (p = 0.06 for two sided t-test, p,0.05 for one sided t-test) compared to normoxic conditions (Panel B). Each experiment
was run in duplicate and changes in mRNA levels were expressed as DDCt values and presented as relative to the mean of C57BL/6J mice (Panel A) or
normoxia (Panel B). Values are mean6SD of C57BL/6J normoxia n = 4; Apoe2/2 normoxia n = 6; Apoe2/2 hypoxia n= 7. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0041786.g003
Figure 4. CysLT1 receptor is expressed in cardiac mouse tissue. Immunohistochemistry analysis confirms CysLT1 receptor expression in
mouse heart tissue notably in endothelial cells. The panels show representative immunostaining for CysLT1 receptor expression in (A) Apoe2/2
without hypoxia; (B) Apoe2/2 following hypoxic stress and (C) negative controls. The arrows point to positive staining cells. The results are
representative of staining performed in n= 6 per group.
doi:10.1371/journal.pone.0041786.g004
Leukotriene Signaling in Heart Disease
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41786
CysLT1. Administration of this drug reduced the hypoxic load of
the myocardium to levels equal to those observed in hearts of
Apoe2/2 mice under normoxic conditions. Since expression
of LTC4S was also increased in the heart of Apoe2/2 mice, an
alternative pharmacological approach to block cys-LT signaling
could be inhibition of LTC4S [22]. This strategy may in fact be
even more effective since recent data have shown that there are
multiple, cross-talking, and cross-regulatory receptors for cys-LT
[24,25]. However, to date no selective LTC4S inhibitors have been
developed. The choice of the classical CysLT1 antagonist
montelukast in our study was guided by the selective upregulation
of CysLT1 and the fact that montelukast is a widely prescribed
asthma drug. Since both the endogenous ligands and the synthetic
antagonists are known to display off-target actions, it had been
desirable to study the effects of, e.g. modulatory GPR17 signaling,
a selective LTC4S inhibitor, or additional CysLT1 antagonists.
Due to the lack of sufficiently selective pharmacological tools and
extended time needed for this mouse model, we focused on
montelukast.
In studies of the pathological role of LTs, animal disease models
have been of variable value. For instance, few, if any, mouse
models reproduce human LT-driven asthma and for atheroscle-
rosis, the Apoe2/2 model has provided ambiguous results [16,26].
Therefore, it was of particular interest to compare our data from
the Apoe2/2 model with human tissues. Needless to say, samples
of human tissues that perfectly match the mouse model, or vice
versa, are not available. However, we used a unique collection of
human heart biopsies from both ischemic and non-ischemic parts
of the same heart and could demonstrate similar changes in the
expression levels of LTC4S and CysLT1 as those observed in the
Figure 5. LTC4S enzyme activity is increased in cardiac tissue of Apoe
2/2 mice. LTC4S enzymatic activity is enhanced in Apoe
2/2 mice
compared to C57BL/6J mice under both normoxic (not statistically significant) and hypoxic conditions (#, p,0.05 versus C57BL/6J hypoxia). LTC4S
enzymatic activity was enhanced by 10-fold in Apoe2/2 mice under acute hypoxia compared to normoxia condition (*, p,0.05 versus Apoe2/2
normoxia). Results expressed as LTC4 (pg/mg microsomal pellet) are mean 6 SD of C57BL/6J normoxia n= 3; C57BL/6J hypoxia n = 5; Apoe
2/2
normoxia n = 4; Apoe2/2 hypoxia n= 3.
doi:10.1371/journal.pone.0041786.g005
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Apoe2/2 model (Fig. 7). These data suggest that the chronic
ischemic human heart is also susceptible to increased cys-LT
signaling and that blocking of cys-LT signaling may exert similar
effects in human heart tissue under hypoxic stress. In this context it
is interesting to note that a recent report demonstrates that males
using montelukast have a significantly reduced risk of MI,
supporting the clinical relevance of our work [27].
In conclusion, we have demonstrated that LTC4S and CysLT1
receptor gene expression is up-regulated in the heart and can be
further enhanced by bouts of hypoxic stress in a mouse model of
atherosclerotic heart disease. Blocking cys-LT signaling by
Figure 6. Blocking cys-LT signaling reduces myocardial hypoxic load. Hypoxic myocardial load is significantly upregulated under acute
hypoxic stress in Apoe2/2 (#, p,0.05 versus Apoe2/2 normoxia); pretreatment with Montelukast (Hypoxia+MTK) reduces hypoxic myocardial load to
levels equal to those observed in hearts of Apoe2/2 mice under normoxia (**, p,0.01 versus Apoe2/2 hypoxia) (Panel A). Panel B is a representative
immunostaining for negative control (1) and positive staining (2) with 2 different magnifications. Hypoxyprobe signal was detected and quantified as
described in the methods section. Results of Panel A are expressed as mean6SD of C57BL/6J normoxia n= 4; C57BL/6J hypoxia n = 5; Apoe2/2
normoxia n = 6; Apoe2/2 hypoxia n= 7; Apoe2/2 hypoxia with montelukast pre-treatment n= 7.
doi:10.1371/journal.pone.0041786.g006
Figure 7. Cysteinyl-leukotriene signaling in human heart biopsies. In chronic ischemic myocardium, levels of LTC4S and CysLT1 are
significantly upregulated as compared to non-ischemic myocardium. In each patient a heart biopsy from chronic ischemic area was compared with
a control biopsy from the same patient in a non-ischemic area. Each experiment was run in duplicate and changes in mRNA levels were expressed as
DDCt values and presented as relative to the mean of non-ischemic myocardium. Values are mean 6 SD of n= 14 patients. **, p,0.01.
doi:10.1371/journal.pone.0041786.g007
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montelukast abolishes the aggravated hypoxic load in response to
hypoxia indicating that cys-LTs compromise oxygen supply,
presumably via actions on the myocardial microcirculation. We
also demonstrate a highly similar gene-expression pattern in the
chronic ischemic human heart suggesting that similar mechanisms
are operating in humans. These findings link myocardial hypoxia
to inflammatory cys-LT signaling, vasoconstriction and acute
hypoxic events, and prompts for testing of anti-leukotriene drugs
in humans at risk for decreased blood oxygen content (e.g. sleep
apnea) and with obstructive coronary artery disease.
Materials and Methods
Experimental Protocol
Animal procedures were approved by the Stockholm Ethical
Committee on Animal Experiments (D.Nr. N28/07/N360/07).
Male Apo-lipoprotein E-deficient [Apoe2/2] and C57BL/6J mice
were fed a Western-type diet for 1 year. Apoe2/2 mice were
treated with either vehicle i.p. dimethyl sulfoxide (DMSO) (n= 7,
group A), montelukast 10 mg/kg i.p. (MTK) dissolved in DMSO
(n=7, group B) or left untreated (n= 6, group C). C57BL/6J mice
were treated with vehicle i.p. (DMSO) (n = 5, group D) or left
untreated (n = 4, group E). One hour after treatment, groups A, B,
and D were exposed to hypoxic stress (10% O2) for 30 min.
DMSO and montelukast treatment were repeated 24 h after
hypoxic stress and animals were euthanized at 48 h. 30 min before
euthanasia mice received pimonidazole hydrochloride (60 mg/kg
i.p.; Hypoxyprobe, Chemicon International, Inc., Temecula, CA).
Following perfusion with PBS, the hearts were collected and
divided into thin slices and either embedded in OCT and flash-
frozen or preserved in formaldehyde and paraffin-embedded.
Cardiac troponin-I plasma levels were determined by ELISA (Life
Diagnostics Inc., West Cheater, PA).
Histochemical and Immunohistochemical Analyses
Myocardial sections were stained with hematoxylin eosin. Heart
slices were also incubated with either Hypoxyprobe 1 Mab1
bound to FITC (diluted 1:100, Chemicon International) for 1 h at
room temperature or with CysLT1 receptor rabbit polyclonal
antibody (diluted 1:50, Cayman) overnight at 4uC. Hypoxyprobe
signal was developed using anti-FITC/HRP complex (diluted
1:200, Chemicon International), ABC-PO complex (Vectastain
ABC Kit, PK-6100 standard, Immunokemi), and DAB substrate
(Peroxidase substrate kit, SK-4100, Vector Laboratories) and
counterstained with Mayer’s hematoxylin. Hypoxic area was
quantified using Leica QWin Image analysis software (Leica,
Wetzlar, Germany). CysLT1 receptor signal was developed with
anti-rabbit biotinylated antibody (diluted 1:500, PerkinElmer),
streptavidin-HRP conjugated (diluted 1:100, PerkinElmer), DAB
substrate (Peroxidase substrate kit, SK-4100, Vector Laboratories)
and counterstained with Mayer’s hematoxylin. Picrosirius red
staining was performed on paraffin-embedded heart tissue sections
for 1 hour in saturated picric acid containing 0.1% picrosirius red
(Direct Red 80; Fluka, Buchs, Switzerland).
Terminal Deoxynucleotidyl Transferase (TdT)-mediated
dUTP Nick-end-labeling (TUNEL) Staining
The ApoAlert DNA Fragmentation Assay Kit (Clontech) was
used to detect apoptosis-induced nuclear DNA fragmentation
using a fluorescence assay according to the instructions by the
manufacturer, and expressed as number of apoptotic cells per total
area. Mouse thymus was used as TUNEL staining positive control.
LTC4S Enzyme Assay
Heart microsomal fractions in aliquots of 85 mL, supplied with
GSH (5 mM) and BSA (10 mg/mL), were incubated at RT for
10 min with LTA4 lithium salt (1 mM). Reactions were stopped
with 2 vol. methanol containing 125 pmol of PGB2 as the internal
standard, acidified to pH 5.6 [citrate (0.1 M)-Phosphate (0.2 M)
buffer], and precipitated proteins removed by centrifugation (1000
x g, 4uC, 5 min). LTA4 transformation products were extracted on
a Sep-Pak C18 cartridge (Oasis, Waters), samples eluted in 1 mL
of methanol, dried under a N2 stream, reconstituted in methanol/
water (1:1) and analyzed by RP-HPLC coupled to enzyme-
immunoassay (EIA kit, Cayman Chemical). Control LTA4
incubations with buffer alone or with recombinant LTC4S were
run in parallel.
Human Myocardial Biopsies
All subjects gave informed consent and the investigation was
approved by the ethical committee of Copenhagen (KF 01–225/
01) and the Karolinska Hospital (03–360). A total of 14 patients
(Table 1) with coronary artery disease undergoing elective
coronary artery by-pass grafting (CABG) were included in the
investigation. Transmural ‘‘Tru-cut’’ biopsies (diameter 1–2 mm)
were performed in each patient at 2 different sites of the left
ventricle. The first biopsy site was chosen in an area with chronic
ischemia due to a sub-occluded or occluded coronary artery, with
Table 1. Clinical characteristics of patients.
Patients n=14
Age (years, mean 6 SE) 6862
Sex (M/F) 12/2
Diabetes, n 3
LVEF (%, mean 6 SE) 5563
Hyperlipidemia, n 11
Previous STEMI, n 6
Prior PCI, n 2
Prior CABG, n 0
CCS class (mean 6 SE) 2.460.1
NTG, n 8
b-blocker, n 10
Ca2+ antagonist, n 5
Statin, n 12
Duration of acute myocardial ischemia (minutes, mean [min–
max])
54 (28–100)





2-vessel disease (stenosis .70%), n 5
3-vessel disease (stenosis .70%), n 9
Values are expressed as number (n) of patients, mean 6 standard error of the
mean (SE) or mean with minimum (min) and maximum (max) values. LVEF, left
ventricular ejection fraction determined by echo-cardiography; STEMI, ST-
elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG,
coronary artery by-pass grafting; NTG, long-acting nitrate preparation.
doi:10.1371/journal.pone.0041786.t001
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no macroscopic signs of earlier infarction or fibrotic scar tissue.
The second site was a myocardial region without ischemia.
RNA Isolation, cDNA Synthesis, and Real-time
Quantitative RT-PCR
RNA from left ventricular mouse heart tissue and human left
ventricular heart biopsies was isolated with RNeasy mini kit
(Qiagen) according to the manufacturer’s instructions. Quantity
and quality was controlled using an Agilent Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA, USA). Complementary
DNA (cDNA) was reverse transcribed from 0.5–1 mg of total RNA
using random hexamer primers. Quantitative real-time PCR was
performed on an ABI Prism 7700 sequence detector (Applied
Biosystems, Foster City, CA, USA) with primer and probes
purchased from assay-on-demand (Applied Biosystems). Changes
in mRNA levels were expressed as DDCt using Cyclophilin A as
endogenous control [28].
Statistical Analysis
Two sided parametric t-test, two-way ANOVA with a post hoc
Holm-Sidak test was used to detect statistically significant
differences (p,0.05) unless otherwise indicated. Data are ex-
pressed as mean 6 standard deviation (SD) unless otherwise
indicated.
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